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Abstract
Background: X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural
deafness (DFN2) are allelic syndromes, caused by reduced activity of phosphoribosylpyrophosphate synthetase 1 (PRS-I)
due to loss-of-function mutations in PRPS1. As only few families have been described, knowledge about the relation
between these syndromes, the phenotypic spectrum in patients and female carriers, and the relation to underlying
PRS-I activity is limited.
Methods: We investigated a family with a novel PRPS1 mutation (c.830A > C, p.Gln277Pro) by extensive phenotyping,
MRI, and genetic and enzymatic tests.
Results: The male index subject presented with an overlap of CMTX5 and Arts syndrome features, whereas his sister
presented with prelingual DFN2. Both showed mild parietal and cerebellar atrophy on MRI. Enzymatically, PRS-I activity
was undetectable in the index subject, reduced in his less affected sister, and normal in his unaffected mother.
Conclusions: Our findings demonstrate that CMTX5, Arts syndrome and DFN2 are phenotypic clusters on an
intrafamilial continuum, including overlapping phenotypes even within individuals. The respective phenotypic
presentation seems to be determined by the exact PRPS1 mutation and the residual enzyme activity, the latter being
largely influenced by the degree of skewed X-inactivation. Finally, our findings show that brain atrophy might be more
common in PRPS1-disorders than previously thought.
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Background
Charcot-Marie-Tooth disease-5 (CMTX5, MIM 311070
[1,2]), Arts syndrome (MIM 301835 [3,4]) and X-linked
nonsyndromic sensorineural deafness (DFN2; MIM
304500 [5]) present three clinically distinct but genetically
allelic disorders, caused by reduced phosphoribosylpyro-
phosphate synthetase 1 (PRS1) activity due to PRPS1 mu-
tations [6]. Only three families with CMTX5 and two
families Arts syndrome, respectively, have been reported
worldwide so far [1,3,7]. Thus, evidence is still rare
whether these two disorders are separate entities, or rather
clusters on a phenotypic continuum of PRPS1-related dis-
ease. In addition, knowledge about intrafamilial variability
and phenotypic manifestations in female carriers is
limited.
Here, we report a family with a novel PRPS1missense mu-
tation providing several new insights in PRS-I -hypoactivity
disease. First, features of CMTX5 and Arts syndrome fea-
tures can overlap within individuals, indicating an intraindivi-
dual continuum of these two disorders. Second, CMTX5/
Arts and (prelingual, severe) DFN2 can present within one
and the same family, revealing an intrafamilial continuum
of these disorders. Third, the respective phenotypic
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presentation along the continuous spectrum of PRPS1-re-
lated disease seems to be determined by the exact PRPS1
mutation and the degree of residual PRS-I enzyme activity,
the latter being largely influenced by the degree of skewed
X-inactivation.
Methods
The index patient, his sister and his mother were investi-
gated by (i) detailed clinical examination by a specialist in
rare neurogenetic disorders, (ii) routine laboratory serum
tests including uric acid analysis, (iii) enzymatic analyses
of PRS-I activity in erythrocytes (for methodological de-
tails, see Additional file 1), and (iv) PRPS1 DNA sequence
analysis (for methodological details, see Additional file 2).
Additionally, the index patient and his sister were assessed
by (v) nerve conduction studies, (vi) ophthalmological fun-
duscopy, and (vii) routine brain magnetic resonance im-
aging (MRI).
The frequency of the identified PRPS1 variant was
determined in more than 4,250 X-chromosomes of
European control individuals with unrelated phenotypes
analyzed by exome sequencing (for methodological de-
tails, see [8]). In addition, the frequency of the change
was assessed in the exome variant server (EVS) of the Na-
tional Heart, Lung, and Blood Institute GO Exome Sequen-
cing Project (Seattle, WA, USA; URL: evs.gs.washington.
edu/EVS/) with the corresponding nucleotide positions be-
ing analyzed in >8,000 European and >4,000 African
American alleles, and in the Database of Single Nucleotide
Polymorphisms (dbSNP; Bethesda: National Center for Bio-
technology Information, National Library of Medicine
[dbSNP Build ID: 138]; available from: http://www.ncbi.
nlm.nih.gov/SNP/). In-silico predictions of the pathogen-
icity of genetic variants were performed using PolyPhen-2
[9], SIFT [10] and MutationTaster [11]. The effect of the
amino acid change on the structure of PRPS1 was predicted
using the crystal structure of human PRPS1 from [12]
(PDB entry 2H06; http://www.pdb.org/) as described before
[4]. X-inactivation patterns in female PRPS1 mutation
carriers were tested by using the highly polymorphic
(CAG)n region of the human androgen receptor gene
(HUMARA locus) after methylation-sensitive digestion
with HpaII, as described previously [13]. This study
was carried out in compliance with the Helsinki Dec-
laration, and approved by the Institutional Review
Board of the University of Tübingen, reference number
598/20118O1.
Consent
Written informed consent was obtained from the pa-
tients for the publication of this report and any accom-
panying images.
Results
Clinical assessment
A 36 year-old male patient from non-consanguineous
German parents (subject II-2; for pedigree, see Figure 1A;
for clinical details see Table 1) presented with prelingual
hearing loss since birth, recurrent severe infections from
age 6 to 8 years with subsequent partially remitting bul-
bar paresis and flaccid tetraparesis which never fully re-
solved, and progressive visual loss due to optic atrophy
since age 12 years (current vision at age 36 years: 0.1
right eye, 0.3 left eye). Gait and trunk ataxia started at
age 30, leading to a dependency on a walking-frame at
age 34 years. Disease severity on the Scale for the As-
sessment and Rating of Ataxia (SARA) yielded 14 out of
40 points [14]. Behavioural and mental disturbances
started at age 16 years, yet the patient was still able to
finish secondary school. Already at this time, the patient
showed a severely reduced attention span, mental rigid-
ity, low frustration tolerance and aggression to persons
including family members. He was unable to perceive
and describe his own physical problems during medical
visits, rejected social contacts, and neglected the need
for medical and rehabilitative treatment. In the following
years, he developed attacks of verbal and physical ag-
gression, e.g. repeatedly pulling his mother down to the
floor by her hairs at age 35 years. Cycles of aggressive
and impulsive behaviour alternated rapidly with cycles of
infantile-regressive behaviour, e.g. shouting and crying at
age 35 years when confronted with the need for a medical
blood sampling. The lack of compliance and cooperative
behaviour led to the cessation of examinations required
for pre-surgery evaluation for cochlea implants. His cogni-
tive capacities and insight at age 36 years seemed to be
below the stage of an adolescent, but no formal neuro-
psychological testing was possible given his severe hearing
and visual impairments and lack of cooperative behaviour.
The combined load of physical, mental and behavioural
disturbances required an institutionalization in long-term
care since age 35 years. Cerebral MRI demonstrated mild
cerebellar and parietal cortical atrophy (Figure 2A,B).
Nerve conduction studies showed florid predominant
axonal sensorimotor neuropathy (Table 1) with positive
sharp waves on EMG of the tibial anterior muscle. Re-
peated lab testing revealed markedly increased serum
creatinkinase (>1000 U/l, ref < 190 U/l), probably caused
by progressive muscle cell turnover due to florid periph-
eral neuropathy. In addition, liver transaminases were con-
stantly mildly elevated (AST 60 U/l; ref <50 U/l; ALT 90
U/l; ref < 50 U/l), with abdominal sonography showing no
structural liver abnormalities.
His sister (subject II-1; Figure 1A) had developed prelin-
gual sensorineural hearing loss in the first years of life, with-
out any further signs of neurological dysfunction at current
age of 42 years. This phenotype is fully compatible with the
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diagnosis of X-linked non-syndromic sensorineural hearing
loss (DFN2) [5]. Her MRI showed discrete parietal and
cerebellar atrophy as well (Figure 2C,D). The mother of the
two subjects (subject I-1) did not show any hearing deficit
or neurological dysfunction at the current age of 66 years.
Uric acid in serum was normal in all three subjects (for an
overview of all clinical and lab details, see Table 1).
Serum biomarker and genetic analyses
Based on the initial clinical assumption of an autosomal-
recessive ataxia, the index patient was assessed by exten-
sive serum testing for biomarkers indicative of recessive
ataxias (alpha-feto protein, lactate, vitamin E, very
long chain fatty acids, phytanic acid, coeruloplasmin,
cholesteanol, lysosomal enzymes, carbohydrate-deficient
Figure 1 Pedigree, PRS enzymatic activity, conservation, and predicted protein structural effects of the novel Gln277Pro PRPS1 variant.
(A) Pedigree of the family shows maternal inheritance of the PRPS1 mutation with variable phenotypic severity of disease, reaching from an
unaffected state in the mother (I-1) to a mildly affected DFN2 phenotype in the sister of the index patient (II-1) to a severe Arts/CMTX5 overlap
syndrome in the index patient (II-2). (B) The severity of the phenotype correlated with the PRS1 enzymatic activity in erythrocytes. (C) Protein
alignment demonstrates high conservation for the mutated amino acid position 277 in the PRPS1 protein across mammals and non-mammals.
(D) PRS1 catalyses the synthesis of phosphoribosylpyrophosphate (PRPP) from ribose 5-phosphate (R5P) and ATP, and is thought to be
physiologically functional as a hexamer, consisting of three homodimers arranged in a propeller-like shape. In this hexamer, the N-terminal
domains are located at the centre and the C-terminal domains at the outside. (E) Gln277 is predicted to interact with Gly251, which is close
proximity to the R5P binding site The p.Gln277Pro change will result in a loss of this hydrogen bonding interaction potentially destabilizing the
region surrounding the R5P binding site, thus affecting the PRPS1 catalytic active site.
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transferrin, quantitative assessment of amino acids) [15],
and genetic testing of FRDA, POLG, PEO1/Twinkle,
WFS1, and ABHD12. All results were normal. Sequencing
of PRPS1 revealed a novel hemizygous c.830A > C, p.
Gln277Pro variant changing a highly conserved amino
acid residue (PhyloP score 4.6; Figure 1C), predicted to be
damaging by all in silico predictions (PolyPhen-2 score:
0.991; SIFT score: 0.01; MutationTaster: disease causing),
and not found in 4,200 ethnically-matched control X-
chromosomes or in the 6,500 exomes (= 10,562 alleles) of
the NHLBI Exome Variant Server (EVS). The same variant
was identified in the sister (II-1) and the mother (I-1) of
Table 1 Clinical findings and further investigations in PRPS1 Gln277Pro mutation carriers
Subject II.2 II.1 I.2
Gender m f f
Phenotypic cluster CMTX5/Arts DFN2 None
Current age 36 42 66
Age of onset first symptom Congenital, hearing loss Congenital, hearing loss None
Neurological
Mental retardation (+) progressive aggressive,
childish behavior, starting at age 18
- -
Ataxia (age of onset) +, 30 years - -
Severity of ataxia (SARA score) 14 out of 40 1 out of 40 0 out of 40
Delayed motor development - - -
Loss of deep tendon reflexes + - -
Hearing loss (age of onset) +, congenital +, congenital
Optic atrophy (age of onset) 12 – -
Uric acid overproduction
Gout - - -
Kidney stones - - -
Renal failure - - -
Serum uric acid (ref 3.4-7.0 mg/dl) 4.3 mg/dl 4.4 mg/dl 4.2 mg/dl
Hematopoetic
Recurrent infections (+), only from age 6 to 8 years - -
Anemia - - -
Other
Short stature - - -
Self-injury - - -
Early death - - -
Lab, electrophysiology and MRI investigations
Nerve conduction studies
-Sensory nerve conduction Sur: no SNAP; Rad: no SNAP Sur: normal, Rad: normal n.d.
Sural or radial nerve
-Motor nerve conduction Tib: borderline MNCV (40 m/s; ref > 40 m/s); Uln:
reduced CMAP (2.1 mV; ref: > 4 mV); reduced
MNCV (36 m/s; ref: > 50 m/s)
Tib: normal; Uln: normal
Tibial or ulnar nerve
MRI Mild cerebellar and parietal cortical atrophy Mild cerebellar and
parietal cortical atrophy
n.d.
Serum creatinkinase (ref <180 U/l) 1168 U/l 141U/l 196 U/l
PRS-I enzyme activity (ref 0.41-
1.46 nmol/(min.mg protein)
<0.005 nmol/(min.mg protein) 0.1 nmol/(min.mg protein) 1.04 nmol/(min.mg protein)
This table was designed to show not only those clinical symptoms that are present, but also those that are absent in this index family, yet common in other
PRPS1 patients. The features were selected and extended from de Brouwer et al., 2010 [6]. Legend: m, male; f, female; n.d., not done; ref, reference value; SARA,
scale for the Assessment and Rating of Ataxia, reaching from 0 to 40, with higher scores indicating more severe ataxia; scores < 3 points are considered unspecific.
Sur = sural; Rad = radial; Tib = tibial, Uln = ulnar; SNAP = sensory nerve action potential; SNCV = sensory nerve conduction velocity; CMAP = compound muscle
action potential; MNCV =motor nerve conduction velocity; MRI, magnetic resonance imaging.
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the index patient in a heterozygous state (for electrophero-
grams, see Additional file 3).
Protein structural effects of the PRPS1 mutation
Gln277 is located in the C-terminal domain of PRPS1 and
is close to the catalytic active site, which consists of an
ATP binding site and a ribose-5-P binding site (Figure 1D).
The p.Gln277Pro change results in two sequential pro-
lines, which very likely disrupts the alpha-helical structure
of this short helical segment and destabilizes the C-
terminal PRPS1 domain. In addition, Gln277 interacts
with Gly251, which is close proximity to the R5P binding
site (Figure 1E). The p.Gln277Pro change will result in a
loss of this hydrogen bonding interaction potentially de-
stabilizing the region surrounding the ribose-5-P binding
site, thus affecting the PRPS1 catalytic active site.
When comparing the protein structural effects of all
known PRPS1 mutations and their relations to PRPS1-
phenotypic clusters, the p.Gln277Pro (Q277P) muta-
tion falls in between CMTX5 and Arts syndrome
PRPS1 mutations. Like other Arts syndrome mutations
(and in contrast to CMTX5 PRPS1 mutations), it is
predicted to disrupt the local PRS-I structure. How-
ever, unlike the other Arts syndrome mutations and in
line with the CMTX PRPS1 mutations, it is not pre-
dicted to disturb the allosteric site II or to affect the
dimer interface (Table 2).
Enzyme activity
PRS-I activity was not detectable in erythrocytes the
index patient II-2 (<0.005 nmol/[min.mg protein];
reference value: 0.41-1.46 nmol/[min.mg protein]),
reduced to 0.10 nmol/[min.mg protein] in his sister
(II-1), and normal in their mother (I-1; 1.04 nmol/
[min.mg protein]) (Figure 1B).
X- chromosome inactivation (XCI)
XCI was extremely skewed (defined as ratio > 90%:10%
[16]) in II-1 (94%:6%), but only moderately skewed in I-1
(80%:20%).
Figure 2 Brain magnetic resonance imaging (MRI) of the two affected siblings. MRI shows diffuse parietal atrophy (arrows in A, C) and mild
cerebellar atrophy (arrows in B, D) in the index patient II-2 at age 31 years (upper row) as well as in his sister II-1 at age 38 years (lower row)
(A, C T1 axial; B, FLAIR coronar; D T2 axial).
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Discussion
Here we report a family with a novel PRPS1 mutation
which provides new insights in PRPS1-related disease. The
index patient (subject II-2) showed an overlapping pheno-
type combining features of both CMTX5 and (mild, rela-
tively late-onset) Arts syndrome. Prelingual hearing loss,
optic atrophy with onset in the teens and severe sensori-
motor neuropathy are part of the classical CMTX5 trias
[2]. However, recurrent infections in childhood leading to
acute deteriorations of slowly progressive muscle weakness,
severe ataxia leading to walker-dependency, mild to moder-
ate mental and behavioural deficits, and institutionalization
in homes for physically and mentally handicapped are all
features not reported in previous CMTX5 subjects, but
known from subjects with Arts syndrome (though usually
in a more severe early-onset form) [3,17]. This shows that
CMTX5 and Arts syndrome can overlap within one and
the same individual, thus indicating a continuous spectrum
of PRS1- hypoactivity disease. This finding corroborates
and extends the recent observation from one individual
with PRS-I superactivity who showed not only signs of
PRS-I superactivity syndrome, but also of Arts syndrome
[18]. Taken together, these findings indicate that both PRS1
superactivity and PRS-I hypoactivity disorders form a con-
tinuous gradual spectrum of disease.
The notion of a continuous disease spectrum of PRS1-
hypoactivity disorders is further supported by our obser-
vation that a CMTX5/Arts overlapping phenotype can
co-occur within the same family as a DFN2 phenotype
(subject II-1), demonstrating an intrafamilial continuum
of these three clusters of PRS-I hypoactivity diseases. So
far, CMTX5, Arts syndrome and DFN2 were only re-
ported in different families, not within the same family
[6]. An earlier report already indicated that some sub-
jects can present with an only incomplete presentation
of a PRPS1 disease cluster (e.g. absence of optic atrophy
in CMTX5 subjects [7]). Taken together, these findings
suggest a continuous spectrum of PRPS1 disease fea-
tures, where hearing loss, peripheral neuropathy, optic
atrophy, ataxia, cognitive deficits and recurrent infec-
tions are central, yet variable phenotypic features. Along
this spectrum, the established PRPS1 disease clusters are
Table 2 Predicted structural effects of known PRPS1 mutations
Mutation Disturbance oflocal structure
Affecting dimer
interface
Affecting trimer
interface
Disturbance of
ATP binding site
Disturbance of
allosteric site I
Disturbance of
allosteric site II Neuropathy
PRS-I superactivity
p.D52H + - + - + - -
p.N114S - + + - +/− +/− +
p.L129I + - - - - + +
p.D183H - + - - +/− +/− +
p.A190V + + - - +/− +/− +
p.H193L** - + - - +/− +/− -
p.H193Q - + - - +/− +/− +
p.V142L + + - - - + +
Arts syndrome
p.Q133P + + - + +/− + +
p.L152P + + - + +/− + +
p.Q277P + - +/− + - - +
CMTX5
p.E43D - - + + + - +
p.M115T - - + + + - +
p.A121G + - +/− +/− +/− - +
DFN2
p.D65N - - + - - - ?
p.A87T + - - - - - ?
p.I290T + - - - - - ?
p.G306R - - + - - - ?
When comparing the protein structural effects of all known PRPS1 mutations and their relations to PRPS1-phenotypic clusters, the p.Gln277Pro mutation falls in
between CMTX5 and Arts syndrome PRPS1 mutations. Like other Arts syndrome mutations (and in contrast to CMTX5 PRPS1 mutations), it is predicted to disrupt
the local PRS-I structure. However, unlike the other Arts syndrome mutations (and in line with other CMTX PRPS1 mutations), it is not predicted to disturb the allosteric
site II or to affect the dimer interface. This table was selected, updated and extended from de Brouwer et al., 2010 [6]. Please see here also for further references [6].
**This mutation was found in a female patient.
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not separate entities, but endophenotypes on a pheno-
typic continuum.
Female carriers in families with Arts syndrome were
known to sometimes exhibit some hearing impairment
later in life (age >20 years) combined with ataxia and
neuropathy [3,19]; yet prelingual hearing loss starting at
birth - as observed in subject II-1 - has not yet been de-
scribed in these families. Female carriers in families with
CMTX5 are noted to be asymptomatic [1]. Our findings
indicate that these current notions and corresponding
counselling recommendations of female carriers in fam-
ilies with CMTX5 [1] or Arts syndrome [3] should be re-
vised: female carriers in families with these phenotypic
clusters can show symptoms already very early in life,
leading to substantial impairment in everyday social life.
How might this intrafamilial continuum of PRPS1 dis-
ease clusters be explained? Our results indicate that the
respective phenotypic presentation seems to be deter-
mined by (1.) the exact PRPS1 mutation (in males) and
(2.) the residual enzyme activity, which in turn is largely
influenced by the degree of skewed X-inactivation (in fe-
males). The predicted structural effects of the p.Gln277Pro
mutation fall in between those of the CMTX5 and Arts
syndrome PRPS1 mutations (Table 2), thus explaining the
CMTX/Arts syndrome overlapping phenotype in the male
index patient II-2. PRS-I enzyme activity was not detect-
able in this male subject with the most complex and se-
vere phenotype, while it was moderately reduced in his
sister II-1 with a nonsyndromic hearing loss phenotype
(DFN2), and normal in his unaffected mother I-1.
(Figure 1B). The lack of detectable PRS-I activity in sub-
ject II-2 might explain why his phenotypic presentation
included components of the Arts cluster, as absence of
PRS-I activity has already been reported for patients with
a pure Arts phenotype [4]. The residual PRS-I activity in
the female carriers (I-1; II-1) might be explained by com-
pensation through the second (intact) X chromosome.
PRS-I activity was lower in subject II-1 than in subject I-1,
most likely due to severely skewed X-chromosome inacti-
vation which was observed in this subject. Alternatively,
tissue-specific control of other genetic and epigenetic
mechanisms might explain the differences in PRS1 activity
between I-1 and II-1, e.g. the regulation of PRPS1 by
microRNA-376 [17] and difference in expression levels
and function of the other three PRS isoforms [6]. Our
finding of a clinico-enzymatic correlation between enzym-
atic activity and disease severity indicates that PRS-I activ-
ity may serve as a blood biomarker for PRPS1 disease and
may help to corroborate pathogenicity of novel PRPS1 var-
iants of unknown significance. It also suggests that it
might serve as an interesting readout and surrogate par-
ameter for treatment efficacy.
So far, cerebral MRI abnormalities have been ob-
served neither in CMTX5 nor in Arts syndrome [3],
yet such abnormalities are likely given the wide range
of clinical central nervous abnormalities in PRPS1-dis-
orders, in particular in Arts syndrome. Here we show
that mild signs of cerebellar and parietal atrophy can
be seen in both subject II-2 and subject II-1, thus pro-
viding first evidence for structural central nervous
system damage in PRPS1- disease. As atrophy is very
mild, it might have been present also in previous
PRPS1 subjects, yet not been recognized. Our finding
of a subject with adolescent-onset ataxia with neur-
opathy, optic atrophy, hearing loss, and mild atrophy
of the cerebellum without evidence of neurological
disease in the parental generation places PRPS1-dis-
ease in the differential diagnosis of many adult-onset
autosomal-recessive and mitochondrial ataxias where
such findings are common and which might be mimicked
by PRPS1-disease. This differential diagnosis includes
e.g. OPA3/Type III methylglutaconic aciduria (MIM
606580), OPA1 (MIM 605290) or Wolfram Syndrome
(MIM 606201).
Conclusions
Our findings indicate that CMTX5, Arts syndrome and
DFN2 are phenotypic clusters on a continuous intraindivi-
dual and intrafamilial spectrum of PRPS1-disease. The re-
spective phenotypic presentation seems to depend on the
exact PRPS1 mutation and the residual enzyme activity
and skewed X-inactivation, respectively.
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